Definition and epidemiology
Restless legs syndrome (RLS), also called Willis-Ekbom disease, is a chronic neurologic sensorimotor disorder defined by an urge to move the legs that is typically accompanied by uncomfortable sensations.
- Prevalence is estimated at roughly 5-10% of adults in Western populations, with lower rates reported in Asian populations.
- Women are affected about 1.5-2 times more often than men, partly related to pregnancy and iron status.
- Prevalence increases with age, though a childhood/adolescent form exists and is likely underdiagnosed.
- Up to one-fifth of pregnant women experience RLS symptoms, usually in the third trimester, which often resolve after delivery.
- RLS is classified as primary (idiopathic, often familial) or secondary (associated with iron deficiency, pregnancy, end-stage renal disease, or peripheral neuropathy).
- RLS = urge to move legs, worse with rest, worse at night, relieved by movement — all four criteria required for diagnosis.
- Check serum ferritin in every RLS patient; treat iron deficiency even without anemia (ferritin <75 ng/mL is the threshold used clinically).
- Alpha-2-delta ligands (gabapentin, pregabalin) are now favored first-line for chronic RLS over dopamine agonists.
- Dopamine agonists (pramipexole, ropinirole) cause augmentation and impulse control disorders with long-term use.
- RLS is common in pregnancy (third trimester) and end-stage renal disease/dialysis patients.
- Periodic limb movements of sleep are seen in up to 80-90% of RLS patients but are not required for diagnosis.
- Avoid chronic daily levodopa in RLS due to high risk of augmentation.
- Medications like metoclopramide, antipsychotics, and SSRIs/SNRIs can trigger or worsen RLS.
Etiology and risk factors
The exact cause is not fully understood, but dysregulation of brain iron metabolism and dopaminergic signaling in the central nervous system is central to current models.
Primary (idiopathic) RLS
- Strong genetic component; family history is common, especially in early-onset disease.
- Several gene loci (e.g., BTBD9, MEIS1) have been associated with increased risk.
Secondary RLS and risk factors
- Iron deficiency (even without frank anemia) is the most important reversible contributor; low ferritin correlates with symptom severity.
- Pregnancy, especially third trimester.
- End-stage renal disease / dialysis — RLS is common in this population.
- Peripheral neuropathy and certain myelopathies.
- Medications that can trigger or worsen RLS: dopamine antagonists (antipsychotics, antiemetics like metoclopramide), most antidepressants (SSRIs, SNRIs, mirtazapine), and sedating antihistamines.
- Other associations: caffeine, alcohol, sleep deprivation, obesity, and smoking.
Pathophysiology
RLS is thought to arise from a combination of brain iron insufficiency and altered dopaminergic neurotransmission, despite normal serum iron in many patients.
- Iron is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis; reduced brain (particularly substantia nigra) iron stores are seen on imaging and autopsy studies in RLS patients even when systemic iron is normal.
- This relative central iron deficiency is thought to impair dopaminergic signaling, which paradoxically explains why both dopamine agonists (short-term benefit) and dopamine depletion/blockade (symptom worsening) affect RLS.
- A circadian component exists: dopamine levels and RLS symptoms both fluctuate with time of day, worsening in the evening and night, which parallels circadian dips in central dopamine activity.
- Augmentation (see Management) is believed to result from dopaminergic receptor downregulation and desensitization with chronic dopaminergic therapy, leading to earlier onset, increased intensity, and spread of symptoms over time.
Clinical features
Diagnosis of RLS is clinical, based on validated essential criteria.
Essential diagnostic criteria (all must be present)
- An urge to move the legs, usually but not always accompanied by, or felt to be caused by, uncomfortable sensations (e.g., crawling, tingling, pulling, aching).
- Symptoms begin or worsen during periods of rest or inactivity (sitting or lying down).
- Symptoms are partially or totally relieved by movement (walking, stretching), at least as long as the activity continues.
- Symptoms are worse in the evening or night than during the day, or occur only in the evening/night.
Supportive features
- Positive family history.
- Response to dopaminergic therapy.
- Periodic limb movements of sleep (PLMS) on polysomnography, present in up to 80-90% of RLS patients.
- Sensations are typically bilateral (though can be asymmetric), located deep in the legs rather than on the skin surface, and essentially never purely painful without the urge-to-move component.
Diagnosis
RLS is a clinical diagnosis; no single test confirms it, but workup targets reversible secondary causes.
- History: confirm the four essential criteria above; use a validated questionnaire if needed (e.g., International RLS Study Group rating scale) to assess severity.
- Serum ferritin is the key initial test; a ferritin below roughly 75 ng/mL is considered a trigger for iron therapy in RLS even without anemia.
- Additional labs as indicated: complete blood count, renal function, fasting glucose, and TSH to screen for contributing conditions (anemia, renal failure, diabetes-related neuropathy, thyroid disease).
- Polysomnography is not required for diagnosis but may be used if another sleep disorder (e.g., obstructive sleep apnea) is suspected or if periodic limb movement disorder needs characterization.
- Nerve conduction studies/EMG are reserved for atypical presentations suggesting peripheral neuropathy or radiculopathy.
Differential diagnosis
- Peripheral neuropathy — sensory symptoms are typically constant, not strictly rest-related, and not relieved by movement in the same characteristic way.
- Nocturnal leg cramps — sudden, painful muscle contractions, not an urge to move, and movement does not provide the same characteristic relief.
- Akathisia (drug-induced, e.g., antipsychotics) — generalized restlessness without the focal leg sensory component or strict circadian pattern.
- Peripheral vascular disease / claudication — pain is exertional (worse with activity, relieved by rest), the opposite pattern from RLS.
- Periodic limb movement disorder — PLMS can occur without waking urge-to-move symptoms; many RLS patients have PLMS, but PLMS alone without the clinical urge does not meet RLS criteria.
- Painful legs and moving toes syndrome and positional discomfort are rarer mimics.
Management
Management is guided by symptom frequency/severity and should begin with correcting reversible causes.
General and lifestyle measures
- Reduce or eliminate aggravating factors: caffeine, alcohol, nicotine, and RLS-aggravating medications where possible.
- Moderate regular exercise and good sleep hygiene.
- Mental alerting activities during prolonged sitting (e.g., travel) can help.
Iron therapy
- Oral iron supplementation is recommended when ferritin is low (generally under ~75 ng/mL); IV iron is used for refractory cases or when oral iron is poorly tolerated or ineffective.
Pharmacologic therapy for intermittent/mild symptoms
- Low-dose, non-ergot dopamine agonists or alpha-2-delta ligands can be used as needed.
Pharmacologic therapy for chronic/persistent symptoms
- Alpha-2-delta calcium channel ligands (gabapentin, gabapentin enacarbil, pregabalin) are now generally preferred as first-line for chronic RLS by most current guidelines, especially when pain, anxiety, or insomnia coexist, because they avoid augmentation.
- Dopamine agonists (pramipexole, ropinirole, rotigotine) are effective but carry risk of augmentation (symptoms start earlier in the day, become more intense, and spread to other body parts with chronic use) and impulse control disorders (compulsive gambling, shopping, hypersexuality); many societies now recommend reserving these for cases where alpha-2-delta ligands are ineffective or contraindicated.
- Low-dose opioids (e.g., oxycodone) may be used in refractory, severe cases under careful monitoring.
- Avoid levodopa for chronic daily use due to high augmentation risk; it is best reserved for intermittent or diagnostic use.
- Guideline consensus (AASM, European and US movement disorder societies) has shifted over the past decade away from dopamine agonists as first-line, favoring alpha-2-delta ligands, largely due to augmentation and impulse-control risks — this is an important and testable change in management philosophy.
Complications and prognosis
- Chronic sleep-onset and sleep-maintenance insomnia leading to daytime fatigue, impaired concentration, and reduced quality of life.
- Increased risk of depression and anxiety.
- Augmentation is the most important treatment-related complication, specific to dopaminergic therapy.
- RLS has been associated with increased cardiovascular risk in epidemiologic studies, though causality is not firmly established.
- Course is often chronic and progressive in primary RLS, while secondary RLS (pregnancy-related, iron-deficiency-related) may resolve once the underlying cause is treated or resolved (e.g., postpartum).
- With appropriate management, most patients achieve good symptom control, though some develop treatment-refractory or augmented disease requiring medication rotation.
URGE: Urge to move legs, Rest-induced, Gets better with movement, Evening/night worse.
Practice questions
1. A 52-year-old woman reports an uncomfortable crawling sensation in both legs that occurs every evening while watching television. The sensation improves when she gets up and walks around but returns when she sits back down. Her symptoms have been present for 8 months and are affecting her sleep. Neurologic exam is normal. Which of the following laboratory tests should be obtained first?
2. A 68-year-old man with RLS has been on pramipexole for 3 years. Over the past 6 months, his symptoms have started earlier in the afternoon instead of only at night, have become more intense, and now also involve his arms. Which phenomenon best explains this clinical course?
3. A 29-year-old woman at 32 weeks' gestation reports a worsening urge to move her legs at night over the past month, with mild relief from walking. Ferritin is low. Which of the following is the most appropriate initial management?
Frequently asked questions
What causes restless legs syndrome?
RLS is caused by a combination of genetic predisposition and disrupted brain iron and dopamine handling, even when blood iron levels appear normal. Common secondary triggers include iron deficiency, pregnancy, end-stage renal disease, and peripheral neuropathy. Certain medications, including antipsychotics, antiemetics, and most antidepressants, can also provoke or worsen symptoms. In many cases a clear single cause is never identified, especially in idiopathic familial RLS.
What are the first symptoms of restless legs syndrome?
The first symptom is usually an uncomfortable, hard-to-describe sensation deep in the legs (crawling, tingling, pulling) paired with a strong urge to move them. It typically appears when sitting or lying still, especially in the evening or at night, and improves temporarily with walking or stretching. Many people initially mistake it for ordinary leg discomfort or anxiety-related restlessness before recognizing the pattern.
How is restless legs syndrome diagnosed?
RLS is diagnosed clinically using four essential criteria: an urge to move the legs with uncomfortable sensations, onset or worsening during rest, relief with movement, and worsening in the evening or night. There is no blood test or imaging study that confirms RLS, but serum ferritin is checked in every patient to identify iron deficiency as a treatable contributor. Polysomnography is only used if another sleep disorder is suspected.
Is restless legs syndrome curable?
RLS is generally not curable but is highly manageable, and secondary forms can resolve completely once the underlying cause is treated. Pregnancy-related RLS typically disappears after delivery, and iron-deficiency-related RLS often improves significantly with iron repletion. Primary (idiopathic) RLS tends to be a chronic, sometimes progressive condition that is controlled with lifestyle changes and medication rather than cured outright.
Restless legs syndrome vs peripheral neuropathy — what is the difference?
RLS causes an urge to move the legs with sensations that specifically worsen at rest and at night and are relieved by movement, while peripheral neuropathy causes relatively constant numbness, tingling, or burning that does not follow this strict rest-and-movement pattern. Neuropathy is often associated with reduced reflexes, sensory loss on exam, or diabetes/alcohol use history, whereas RLS exam findings are typically normal. The two conditions can coexist, since neuropathy is a recognized risk factor for secondary RLS.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: G25.8
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.